Shares of Regeneron Pharmaceuticals Inc. slipped 3.63% to $527.78 Friday, on what proved to be an all-around poor trading ...

The primary endpoint of comprehensive disease control was defined as a combination of clinical remission (CDAI under 150; ...

Regeneron Pharmaceuticals Inc. closed 54.78% below its 52-week high of $1,211.20, which the company reached on August 27th.

A prior phase II trial had shown that BCG revaccination in teens led to 45.4% efficacy in reversion from positive to negative ...

The S&P 500 slipped 0.8% on Tuesday, May 6, 2025, falling for a second straight day as investors awaited news on U.S. tariff ...

An ex-assistant U.S. attorney in Los Angeles has filed a claim calling his dismissal “unlawful” and alleging it was motivated ...

The findings are based on dietary recall, which points toward further research rather than specific recommendations.

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

We recently compiled a list of the 11 Cheap ESG Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

This was the stock's second consecutive day of losses.

The new plans are in addition to $21B that the drug manufacturer has already committed to U.S. research, development and ...